Physician profile
Chloe Murray
NPI 1871159376
$1,109.20
in general payments reported to CMS, 2019-2025
22 companies · $306 in 2025
The $306 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $72.51 · 2024: $730 · 2025: $306.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,109.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,109.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $338.97 | 2023-2025 | |
| Neurocrine Biosciences, INC. | $100.17 | 2024-2025 | Ingrezza |
| Corium, LLC | $58.79 | 2024 | Azstarys |
| Vanda Pharmaceuticals INC. | $53.29 | 2024-2025 | Fanapt, Hetlioz |
| Axsome Therapeutics, INC. | $51.73 | 2024-2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $50.28 | 2024 | Spravato |
| Takeda Pharmaceuticals U.S.A., INC. | $49.31 | 2024 | Trintellix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $47.39 | 2024-2025 | Xifaxan |
| Otsuka America Pharmaceutical, INC. | $44.66 | 2024-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Supernus Pharmaceuticals, INC. | $37.25 | 2024 | Qelbree |
| Ironshore Pharmaceuticals INC. | $33.23 | 2024 | |
| Novo Nordisk INC | $32.46 | 2024-2025 | |
| Lilly USA, LLC | $31.37 | 2023 | Mounjaro, Jardiance |
| Exact Sciences Corporation | $29.42 | 2025 | Cologuard Collection Kit |
| Noven Therapeutics, LLC | $24.14 | 2025 | Xelstrym |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $23.83 | 2025 | Jornay Pm |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $21.26 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $19.74 | 2024 | |
| Xeris Pharmaceuticals, INC. | $16.49 | 2025 | Gvoke Hypopen |
| Hikma Pharmaceuticals USA | $16.29 | 2024 | Ryaltris |
| Astrazeneca Pharmaceuticals LP | $15.34 | 2025 | Airsupra |
| Inspire Medical Systems, INC. | $13.79 | 2025 | Inspire |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chloe Murray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.